Trial Profile
A Pilot Study to Evaluate Efficacy and Safety of Multiplexed shRNA-modified CD34+ Cells in HIV-infected Patients.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Feb 2022
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; ShRNA modified CD34 cells Kanglin Biotech (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 18 Feb 2020 Planned End Date changed from 20 Jan 2020 to 31 Dec 2020.
- 18 Feb 2020 Planned primary completion date changed from 15 Jul 2018 to 15 Dec 2020.
- 14 May 2018 New trial record